{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004083","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.667192+00:00","generated_at":"2026-06-06T15:55:05.336364+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RenovoRx closes $6.1M private placement; insider participation; exec salary cuts 25%","bullets":["Raised gross proceeds of $6,111,695 via private placement of 6,133,414 shares + warrants at $0.99/share (non-insiders) and $1.22 (insiders).","Insiders including management and board purchased shares at $1.22, showing confidence.","25% reduction in base salaries for CEO Shaun Bagai, Ramtin Agah, Angela Gill Nelms until board decides otherwise.","2023 bonuses paid in 10-year options at $1.08 exercise price instead of cash.","Second interim analysis of TIGeR-PaC Phase III trial expected at 52nd event (death) in late 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004083","json":"https://secwatch.observer/filing/0001493152-24-004083.json","markdown":"https://secwatch.observer/filing/0001493152-24-004083.md","text":"https://secwatch.observer/filing/0001493152-24-004083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/0001493152-24-004083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:55:05.336364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c1530f994dc97fb2585a010b0a536ff59d008d5","claim":"RenovoRx, Inc. entered into Subscription Agreements with 92 accredited investors valued at $6,111,695 (effective 2024-01-26).","evidence_excerpt":"On January 26, 2024, RenovoRX, Inc. (the “Company,” “us,” “we,” or “our”) entered into a series of subscription agreements, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K (the “Subscription Agreements”), in connection with a private placement offering to 92 accredited investors (the “Investors”), which was also closed on January 26, 2024, and pursuant to which we raised aggregate gross proceeds of $6,111,695 (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/0001493152-24-004083-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"92 accredited investors"},{"label":"Value","value":"$6,111,695"},{"label":"Effective","value":"2024-01-26"}],"fact_type":"material_agreement"},{"claim_id":"e0bc8e7d8e562cc2855e23c68d5abdccb782e753","claim":"RenovoRx, Inc. entered into Placement Agent Agreement with Paulson Investment Company, LLC (effective 2023-11-14).","evidence_excerpt":"On November 14, 2023, in connection with the Offering, the Company entered into a placement agent agreement, a copy of which is filed as Exhibit 10.4 to this Current Report on Form 8-K (the “Placement Agent Agreement”) with Paulson Investment Company, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s placement agent in connection with the Offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224004083/0001493152-24-004083-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Paulson Investment Company, LLC"},{"label":"Effective","value":"2023-11-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}